Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy

European Heart Journal Cardiovascular Imaging

Volumn 15, Issue 7, 2014, Pages 776-786

  Jellis, Christine L ^a   Sacre, Julian W ^a   Wright, Jeremy ^b   Jenkins, Carly ^a   Haluska, Brian ^a   Jeffriess, Leanne ^a   Martin, Jennifer ^a   Marwick, Thomas H ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GREENSLOPES PRIVATE HOSPITAL   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Backscatter; Fiabetic cardiomyopathy; Fiastolic dysfunction; Myocardial fibrosis; Pro collagen biomarkers; Spironolactone; T1 mapping

Indexed keywords

ALBUMIN; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PRO COLLAGEN TYPE I; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE;

ADULT; AMINO TERMINAL SEQUENCE; ANTHROPOMETRY; ARTICLE; BIOCHEMISTRY; CARBOXY TERMINAL SEQUENCE; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DIARRHEA; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HEART RATE; HEMODYNAMIC STRESS; HIP CIRCUMFERENCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; XEROSTOMIA; AGED; ANALYSIS OF VARIANCE; BLOOD; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; PROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SINGLE BLIND PROCEDURE; STATISTICAL MODEL; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; SPIRONOLACTONE; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904088094     PISSN: 20472404     EISSN: 20472412     Source Type: Journal    
DOI: 10.1093/ehjci/jeu013     Document Type: Article

References (56)

1. Fang ZY, Schull-Meade R, Downey M, Prins J, Marwick TH. Determinants of subclinical diabetic heart disease. Diabetologia 2005;48:394-402. (Pubitemid 40543314)
2. Jellis CL, Jenkins C, Leano R, Martin JH, Marwick TH. Reduced end-systolic pressure-volume ratio response to exercise: a marker of subclinical myocardial disease in type 2 diabetes. Circ Cardiovasc Imaging 2010;3:443-9.
3. Giorda CB, Cioffi G, de Simone G, Di Lenarda A, Faggiano P, Latini R et al. Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. Eur J Cardiovasc Prev Rehabil 2011;18:415-23.
4. Marwick TH. Diabetic heart disease. Postgrad Med J 2008;84:188-92.
5. Jellis CL, Stanton T, Leano R, Martin J, Marwick TH. Usefulness of at rest and exercise hemodynamics to detect subclinical myocardial disease in type 2 diabetes mellitus. Am J Cardiol 2011;107:615-21.
6. Wong C, Marwick TH. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med 2007;4:436-43. (Pubitemid 47189016)
7. Diez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich) 2007;9:546-50.
8. Brindley DN, Kok BP, Kienesberger PC, Lehner R, Dyck Jr. Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization. Am J Physiol Endocrinol Metab 2010;298: E897-908.
9. Robins SP. Biochemistry and functional significance of collagen cross-linking. Biochem Soc Trans 2007;35:849-52. (Pubitemid 350206380)
10. Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 2011;4:44-52.
11. Sciarretta S, Paneni F, Palano F, Chin D, Tocci G, Rubattu S et al. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci (Lond) 2009;116:467-77.
12. Kania G, Blyszczuk P, Eriksson U. Mechanisms of cardiac fibrosis in inflammatory heart disease. Trends Cardiovasc Med 2009;19:247-52.
13. van den Borne SW, Diez J, Blankesteijn WM,Verjans J, Hofstra L, Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol 2010;7:30-7.
14. Hughes SE. The pathology of hypertrophic cardiomyopathy. Histopathology 2004;44: 412-27. (Pubitemid 38725670)
15. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65.
16. Vantrimpont P, Rouleau JL, Ciampi A, Harel F, de Champlain J, Bichet D et al. Two-year time course and significance of neurohumoral activation in the survival and ventricular enlargement (save) study. Eur Heart J 1998;19:1552-63. (Pubitemid 28470478)
17. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Consensus trial study group. Circulation 1990;82:1730-6. (Pubitemid 20367976)
18. Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med 1999;341: 753-5. (Pubitemid 29407377)
19. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709-17. (Pubitemid 29407370)
20. Pitt B, RemmeW, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21. (Pubitemid 36384098)
21. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004;110:558-65. (Pubitemid 39031173)
22. Orea-Tejeda A, Colin-Ramirez E, Castillo-Martinez L, Asensio-Lafuente E, Corzo-Leon D, Gonzalez-Toledo R et al. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Rev Invest Clin 2007;59:103-7. (Pubitemid 47039542)
23. Picano E, Pelosi G, Marzilli M, Lattanzi F, Benassi A, Landini L et al. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 1990;81:58-64. (Pubitemid 20031767)
24. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced t1 mapping. J Am Coll Cardiol 2008;52:1574-80.
25. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T, Marwick TH. A randomized study of the beneficial effects of aldosterone antagonism on lv function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc Imaging 2011;4:1239-49.
26. Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC et al. Serum carboxyterminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000;101:1729-35. (Pubitemid 30196635)
27. Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995; 75:913-8.
28. Jensen LT, Horslev-Petersen K, Toft P, Bentsen KD, Grande P, Simonsen EE et al. Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction. Circulation 1990;81:52-7. (Pubitemid 20031766)
29. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, PatleA et al. Diastolic heart failure: Evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007;115:888-95. (Pubitemid 46294729)
30. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Murphy NF, ConlonC et al. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail 2009;11:191-7.
31. Alla F, Kearney-Schwartz A, Radauceanu A, Das Dores S, Dousset B, Zannad F. Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. Eur J Heart Fail 2006;8:147-53. (Pubitemid 43240848)
32. Sun JP, Popovic ZB, Greenberg NL, Xu XF, Asher CR, Stewart WJ et al. Designation of tissue Doppler normal range. In: Marwick TH, Yu CM, Sun JP (eds). Myocardial Imaging-Tissue Doppler and Speckle Tracking. Oxford: Blackwell Publishing, 2007, pp. 36-51.
33. Schulz KF, Altman DG, Moher D. Consort 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:726-32.
34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28: 412-9. (Pubitemid 15018832)
35. Nagueh SF, Appleton CP, Gillebert TC, Marino PN,Oh JK, Smiseth OA et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107-33.
36. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de DivitiisO et al. Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992;20:1251-60.
37. Jellis C, Wright J, Kennedy D, Sacre J, Jenkins C, Haluska B et al. Association of imaging markers of myocardial fibrosis with metabolic and functional disturbances in early diabetic cardiomyopathy. Circ Cardiovasc Imaging 2011;4:693-702.
38. Messroghli DR, Nordmeyer S, Dietrich T, Dirsch O, Kaschina E, Savvatis K et al. Assessment of diffuse myocardial fibrosis in rats using small-animal look-locker inversion recovery t1 mapping. Circ Cardiovasc Imaging 2011;4:636-40.
39. Shimizu M, Umeda K, Sugihara N, Yoshio H, Ino H, Takeda R et al. Collagen remodelling in myocardia of patients with diabetes. J Clin Pathol 1993;46:32-6. (Pubitemid 23039583)
40. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006;113:1966-73.
41. Brooks BA, Franjic B, Ban CR, Swaraj K, Yue DK, Celermajer DS et al. Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. Diabetes Obes Metab 2008;10:739-46.
42. Ma H, Li SY, Xu P, Babcock SA, Dolence EK, Brownlee M et al. Advanced glycation endproduct (age) accumulation and age receptor (rage) up-regulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med 2009;13:1751-64.
43. Garcia MJ, Thomas JD. Tissue Doppler to assess diastolic left ventricular function. Echocardiography 1999;16:501-8. (Pubitemid 29347497)
44. Hare JL, Brown JK, Marwick TH. Performance of conventional echocardiographic parameters and myocardial measurements in the sequential evaluation of left ventricular function. Am J Cardiol 2008;101:706-11. (Pubitemid 351649349)
45. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 2000;102:1788-94.
46. Pasipoularides A. Evaluation of right and left ventricular diastolic filling. J Cardiovasc Transl Res 2013;6:623-39.
47. Chan AK, Sanderson JE,Wang T, LamW, Yip G,Wang M et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol 2007;50:591-6. (Pubitemid 47199012)
48. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartandependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002;105:2512-7. (Pubitemid 34568973)
49. Lopez B, Querejeta R, Varo N, Gonzalez A, Larman M, Martinez Ubago JL et al. Usefulness of serum carboxy-terminal propeptide of procollagen type i in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001;104:286-91. (Pubitemid 32666949)
50. Iraqi W, Rossignol P, Angioi M, Fay R, Nuee J, Ketelslegers JM et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the eplerenone postacute myocardial infarction heart failure efficacy and survival study (ephesus) study. Circulation 2009;119:2471-9.
51. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (rales). Rales investigators. Circulation 2000;102:2700-6.
52. Campbell DJ, Somaratne JB, Jenkins AJ, Prior DL, Yii M, Kenny JF et al. Impact of type 2 diabetes and the metabolic syndromeon myocardial structure and microvasculature of men with coronary artery disease. Cardiovasc Diabetol 2011;10:80.
53. Konduracka E, Gackowski A, Rostoff P, Galicka-Latala D, FrasikW, PiwowarskaW. Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. Eur Heart J 2007;28:2465-71. (Pubitemid 47614285)
54. Sado DM, Flett AS, Banypersad SM, White SK, Maestrini V, Quarta G et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart 2012;98:1436-41.
55. Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and subclinical myocardial pathology. Eur Heart J 2012;33:1268-78.
56. Ingul CB, Stoylen A, Slordahl SA, Wiseth R, Burgess M, Marwick TH. Automated analysis of myocardial deformation at dobutamine stress echocardiography: an angiographic validation. J Am Coll Cardiol 2007;49:1651-9. (Pubitemid 46551633)